Amneal Pharmaceuticals, Inc. (AMRX) is one of the 13 most undervalued stocks under $20. Piper Sandler raised its price target on the stock to $13 following a Q3 earnings beat that exceeded revenue and earnings estimates. Net revenue for the quarter was $785 million, up 12% from the previous year. Specialty net revenue and revenue for Affordable Medicines both grew 8%, with AvKARE segment revenue surging 24%. Net income stood at $54.4 million, a significant improvement from last year’s net loss of $50.6 million. Diluted EPS was $0.17, beating estimates by four cents. Adjusted EBITDA for the quarter was $160 million, up 1% year-over-year. The company updated its full year 2025 guidance with net revenue expected to range between $3 billion to $3.1 billion, and adjusted EPS anticipated to be between $0.75 and $0.80. The lower end of adjusted EBITDA was raised by $10 million, with the new range between $675 million and $685 million. The stock has seen strong returns in 2025, surging over 50% year-to-date. Amneal Pharmaceuticals, Inc. (AMRX) is a biopharmaceutical company specializing in developing, marketing, and distributing medicines.

Read more at Yahoo Finance: Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)’s Price Target To $13 Following Q3 Earnings Beat